Addition of Immunotherapy to Chemotherapy for Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

The authors conduct a meta-analysis, showing that the addition of programmed death-1/programmed death ligand-1 (PD-L1) blockade to chemotherapy improves progression-free survival in PD-L1 positive metastatic TNBC patients, also in the intention-to-treat population.